The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
Tian Wang,1,* Feng Lin,2,* Yujing Huang,2 Guowei Qian,2 Wenxi Yu,2 Haiyan Hu,2 Tong Ji,3 Lina Tang,2 Yang Yao2 1The Eighth People’s Hospital of Shanghai, Shanghai, People’s Republic of China; 2Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-10-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-combination-of-anlotinib-and-gemcitabinedocetaxel-in-patients-with-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1811229570935816192 |
|---|---|
| author | Wang T Lin F Huang Y Qian G Yu W Hu H Ji T Tang L Yao Y |
| author_facet | Wang T Lin F Huang Y Qian G Yu W Hu H Ji T Tang L Yao Y |
| author_sort | Wang T |
| collection | DOAJ |
| description | Tian Wang,1,* Feng Lin,2,* Yujing Huang,2 Guowei Qian,2 Wenxi Yu,2 Haiyan Hu,2 Tong Ji,3 Lina Tang,2 Yang Yao2 1The Eighth People’s Hospital of Shanghai, Shanghai, People’s Republic of China; 2Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 3Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yang Yao; Lina Tang, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, No. 600 Yishan Road, Xuhui Distinct, Shanghai, 200233, People’s Republic of China, Tel +86 2164369181 ; +86 2164701361, Email yangyao_6@hotmail.com; Tina_8042@hotmail.comPurpose: The options for the second-line treatment of metastatic osteosarcoma are still limited. Anlotinib is a multi-kinase inhibitor which has shown promising efficacy and good tolerability in various cancer types. This retrospective study was conducted to evaluate the efficacy and safety of anlotinib combined with gemcitabine/docetaxel (GD) in patients with metastatic osteosarcoma who have failed first-line chemotherapy.Patients and Methods: The data of patients who received anlotinib combined with GD or GD were collected. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate and safety.Results: From July 2013 to November 2020, a total of 32 patients were enrolled, 13 received anlotinib combined with GD and 19 received GD. Median PFS was 9.0 months (95% CI 6.7– 39.1) in the combination group and 5.0 months (95% CI 1.2– 6.7) in the chemotherapy group. ORR were 38.4% and 15.8%, DCR were 69.2% and 38.1% in the combination and chemotherapy group, respectively. The most common adverse events included fatigue (78.9% in the combination group vs 69.2% in the chemotherapy group), hypertension (46.2% vs 10.5%), diarrhea (38.5% vs 21.1%), hypothyroidism (38.5% vs 15.8%), neutropenia (23.1% vs 36.8%) and AST elevation (30.8% vs 21.1%). The most common grade 3 or worse adverse events included hand-foot reaction (7.7% vs 5.3%), hypothyroidism (15.4% vs 0), neutropenia (0 vs 10.5%).Conclusion: The combination of anlotinib and GD showed favorable efficacy with manageable toxicities compared with GD in the second-line treatment for metastatic osteosarcoma. This combination therapy deserves further investigations in patients with osteosarcoma.Keywords: anlotinib, refractory metastatic osteosarcoma, combination therapy |
| first_indexed | 2024-04-12T10:16:23Z |
| format | Article |
| id | doaj.art-e19264e3a1874354aae0bc66334dcc82 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-12T10:16:23Z |
| publishDate | 2022-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-e19264e3a1874354aae0bc66334dcc822022-12-22T03:37:11ZengDove Medical PressCancer Management and Research1179-13222022-10-01Volume 142945295278748The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard ChemotherapyWang TLin FHuang YQian GYu WHu HJi TTang LYao YTian Wang,1,* Feng Lin,2,* Yujing Huang,2 Guowei Qian,2 Wenxi Yu,2 Haiyan Hu,2 Tong Ji,3 Lina Tang,2 Yang Yao2 1The Eighth People’s Hospital of Shanghai, Shanghai, People’s Republic of China; 2Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 3Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yang Yao; Lina Tang, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, No. 600 Yishan Road, Xuhui Distinct, Shanghai, 200233, People’s Republic of China, Tel +86 2164369181 ; +86 2164701361, Email yangyao_6@hotmail.com; Tina_8042@hotmail.comPurpose: The options for the second-line treatment of metastatic osteosarcoma are still limited. Anlotinib is a multi-kinase inhibitor which has shown promising efficacy and good tolerability in various cancer types. This retrospective study was conducted to evaluate the efficacy and safety of anlotinib combined with gemcitabine/docetaxel (GD) in patients with metastatic osteosarcoma who have failed first-line chemotherapy.Patients and Methods: The data of patients who received anlotinib combined with GD or GD were collected. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate and safety.Results: From July 2013 to November 2020, a total of 32 patients were enrolled, 13 received anlotinib combined with GD and 19 received GD. Median PFS was 9.0 months (95% CI 6.7– 39.1) in the combination group and 5.0 months (95% CI 1.2– 6.7) in the chemotherapy group. ORR were 38.4% and 15.8%, DCR were 69.2% and 38.1% in the combination and chemotherapy group, respectively. The most common adverse events included fatigue (78.9% in the combination group vs 69.2% in the chemotherapy group), hypertension (46.2% vs 10.5%), diarrhea (38.5% vs 21.1%), hypothyroidism (38.5% vs 15.8%), neutropenia (23.1% vs 36.8%) and AST elevation (30.8% vs 21.1%). The most common grade 3 or worse adverse events included hand-foot reaction (7.7% vs 5.3%), hypothyroidism (15.4% vs 0), neutropenia (0 vs 10.5%).Conclusion: The combination of anlotinib and GD showed favorable efficacy with manageable toxicities compared with GD in the second-line treatment for metastatic osteosarcoma. This combination therapy deserves further investigations in patients with osteosarcoma.Keywords: anlotinib, refractory metastatic osteosarcoma, combination therapyhttps://www.dovepress.com/the-combination-of-anlotinib-and-gemcitabinedocetaxel-in-patients-with-peer-reviewed-fulltext-article-CMARanlotinibrefractory metastatic osteosarcomacombination therapy |
| spellingShingle | Wang T Lin F Huang Y Qian G Yu W Hu H Ji T Tang L Yao Y The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy Cancer Management and Research anlotinib refractory metastatic osteosarcoma combination therapy |
| title | The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy |
| title_full | The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy |
| title_fullStr | The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy |
| title_full_unstemmed | The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy |
| title_short | The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy |
| title_sort | combination of anlotinib and gemcitabine docetaxel in patients with metastatic osteosarcoma who have failed standard chemotherapy |
| topic | anlotinib refractory metastatic osteosarcoma combination therapy |
| url | https://www.dovepress.com/the-combination-of-anlotinib-and-gemcitabinedocetaxel-in-patients-with-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT wangt thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT linf thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT huangy thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT qiang thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT yuw thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT huh thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT jit thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT tangl thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT yaoy thecombinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT wangt combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT linf combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT huangy combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT qiang combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT yuw combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT huh combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT jit combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT tangl combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy AT yaoy combinationofanlotinibandgemcitabinedocetaxelinpatientswithmetastaticosteosarcomawhohavefailedstandardchemotherapy |